Carter Bankshares Reports Record Q1 Earnings Driven by Major Loan Sale, Faces $500M Lawsuit
CARE sits 71% above its 52-week low of $15.37 on light trading volume (0.4× avg).
Summary
Carter Bankshares reported record Q1 2026 earnings and a significant reduction in nonperforming loans due to a major loan sale, but now faces a substantial $500 million lawsuit related to the transaction.
Key Events · Earnings and Guidance · CARE
-
Record Q1 Earnings Driven by Loan Sale
Net income surged to $85.8 million ($3.88 diluted EPS) in Q1 2026, up from $9.0 million ($0.39 diluted EPS) in Q1 2025, primarily due to an $80.0 million gain from the sale of a large nonperforming loan portfolio.
-
Significant Improvement in Asset Quality
Nonperforming loans decreased by $220.0 million to $24.0 million, reducing the nonperforming loan ratio from 6.29% to 0.64% of total portfolio loans.
-
New $500M Lawsuit Filed
A lawsuit was filed on April 12, 2026, by the Justice Entities, seeking at least $500 million in direct damages, plus other damages, alleging misconduct related to the aforementioned loan sale.
-
Enhanced Liquidity and Capital Position
Total liquidity sources increased to $1.56 billion from $1.23 billion, and all capital ratios remain well above regulatory 'well-capitalized' thresholds, partly due to the loan sale proceeds being used to repay $178.5 million in FHLB borrowings.
Analysis · CARE · Finance
Carter Bankshares, Inc. reported exceptionally strong first-quarter 2026 results, primarily driven by the successful sale of its largest nonperforming loan relationship (the "Transaction"). This transaction resulted in a $65.0 million gain and a $15.0 million net recovery, significantly boosting net income to $85.8 million and diluted EPS to $3.88, a substantial increase from the prior year. The sale also dramatically improved asset quality, reducing nonperforming loans by $220.0 million and lowering the nonperforming loan ratio from 6.29% to 0.64%. Liquidity and capital ratios also saw favorable impacts. However, the company disclosed a new lawsuit filed on April 12, 2026, by the Justice Entities, seeking at least $500 million in direct damages related to this very loan sale. While the Q1 financial performance is outstanding, the lawsuit introduces a significant legal and financial risk that could materially impact future results.
At the time of this filing, CARE was trading at $26.22 on NASDAQ in the Finance sector, with a market capitalization of approximately $580.9M. The 52-week trading range was $15.37 to $26.58. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.